The aim is to evaluate the efficacy and safety of Jiawei Simiaoyongan granules in treating non-infectious anterior uveitis.
Conducted a randomized open-label trial
Evaluated recurrence rate and symptom relief in patients with NIAU
Assessed safety profile of the treatment
Significant reduction in the recurrence rate of non-infectious anterior uveitis
Alleviation of ocular pain, insomnia, and bitter taste symptoms
Maintained favorable safety profile with minimal adverse effects
Abstract
JWSMYAG can reduce the recurrence rate of NIAU, alleviate ocular pain, insomnia, and bitter taste symptoms in patients with NIAU, and have a favorable safety profile.